Sandoz has announced joint plans with the Austrian government to invest over €150m in antibiotics manufacturing.
Sandoz has announced joint plans with Austria’s government to invest more than €150m ($176m) in antibiotics manufacturing “to drive long-term competitiveness of European production for key antibiotics in Europe” against the backdrop of supply constraints experienced during the COVID-19 pandemic.
The planned combined investment will include “major innovative technology development and implementation for large-scale manufacture of active ingredients for leading...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
